Literature DB >> 16362159

Restoration of peritoneal integrity after withdrawal of peritoneal dialysis: characteristic features of the patients at risk of encapsulating peritoneal sclerosis.

Yasushi Otsuka1, Masaaki Nakayama2, Masato Ikeda2, Ali M Sherif2, Keitaro Yokoyama2, Hiroyasu Yamamoto2, Yoshindo Kawaguchi2.   

Abstract

BACKGROUND: The epidemiological characteristics of encapsulating peritoneal sclerosis (EPS), such as its high incidence in patients with long-term peritoneal dialysis (PD) treatment, and the onset of EPS after patients are switched to hemodialysis (HD) may indicate an activated pathological process after PD withdrawal, especially in long-term PD patients. Accordingly, we aimed to observe changes in peritoneal function after the stoppage of PD, and to clarify the characteristic features of the patients at risk of EPS.
METHODS: Thirty-three patients who were switched from continuous ambulatory peritoneal dialysis (CAPD) to HD were enrolled in this trial. Changes in the dialysate/plasma creatinine (D/P Cr) and CA125 levels in the effluent of the peritoneal equilibration test were observed for 6 months. Furthermore, each patient was followed-up for 36 months after PD withdrawal to monitor for the development of EPS.
RESULTS: D/P Cr decreased significantly, while CA125 levels tended to increase. Nine patients developed EPS during the follow-up period and they specifically showed significant increases of D/P Cr levels and significantly lower levels of CA125 at PD withdrawal. The accumulation of high transporters in the EPS group at 0 and 6 months after PD withdrawal was significant.
CONCLUSIONS: Peritoneal recovery may take place after withdrawal from PD treatment and such recover indicated by improvement of transport states and a rise of the CA125 level. The present study revealed that a high-transport state and lack of increase of CA125 in the effluent were associated with EPS development after PD withdrawal. This may suggest that the lack of peritoneal recovery after PD withdrawal is predictive for EPS development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16362159     DOI: 10.1007/s10157-005-0384-5

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  24 in total

1.  Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis.

Authors:  Misaki Moriishi; Hideki Kawanishi; Toru Kawai; Syunsake Takahashi; Takayuki Hirai; Masayuki Shishida; Hiroshi Watanabe; Naoko Takahashi
Journal:  Adv Perit Dial       Date:  2002

2.  High-transport membrane is a risk factor for encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment.

Authors:  Ryo Yamamoto; Masaaki Nakayama; Toshio Hasegawa; Numata Miwako; Hiroyasu Yamamoto; Keitaro Yokoyami; Masato Ikeda; Naohiko Kato; Hiroshi Hayakawa; Hajime Takahashi; Yasushi Otsuka; Yoshindo Kawaguchi; Tastuo Hosoya
Journal:  Adv Perit Dial       Date:  2002

3.  Sclerosing peritonitis: the experience in Australia.

Authors:  R J Rigby; C M Hawley
Journal:  Nephrol Dial Transplant       Date:  1998-01       Impact factor: 5.992

4.  Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration.

Authors:  K Honda; K Nitta; S Horita; W Yumura; H Nihei; R Nagai; K Ikeda; S Horiuchi
Journal:  Nephrol Dial Transplant       Date:  1999-06       Impact factor: 5.992

5.  Changes in peritoneal coagulation and fibrinolysis after discontinuation of chronic peritoneal dialysis.

Authors:  Sumiko Homma; Yoshinori Masunaga; Megumi Kurosu; Makoto Inoue; Toshihiro Sakurai; Yasushi Asano
Journal:  Perit Dial Int       Date:  2002 Mar-Apr       Impact factor: 1.756

6.  Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group.

Authors:  Y Nomoto; Y Kawaguchi; H Kubo; H Hirano; S Sakai; K Kurokawa
Journal:  Am J Kidney Dis       Date:  1996-09       Impact factor: 8.860

7.  Immunosuppression in sclerosing peritonitis.

Authors:  B J Junor; M A McMillan
Journal:  Adv Perit Dial       Date:  1993

8.  Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats.

Authors:  H Suga; S Teraoka; K Ota; S Komemushi; S Furutani; S Yamauchi; S Margolin
Journal:  Exp Toxicol Pathol       Date:  1995-09

9.  Sclerotic thickening of the peritoneal membrane in maintenance peritoneal dialysis patients.

Authors:  V C Gandhi; H M Humayun; T S Ing; J T Daugirdas; V R Jablokow; S Iwatsuki; W P Geis; J E Hano
Journal:  Arch Intern Med       Date:  1980-09

10.  TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model.

Authors:  Yoko Yoshio; Masanobu Miyazaki; Katsushige Abe; Tomoya Nishino; Akira Furusu; Yohei Mizuta; Takashi Harada; Yoshiyuki Ozono; Takehiko Koji; Shigeru Kohno
Journal:  Kidney Int       Date:  2004-10       Impact factor: 10.612

View more
  2 in total

1.  Risk factors for drainage-requiring ascites after refractory peritonitis in peritoneal dialysis patients.

Authors:  Cheng-Chia Lee; Kun-Hua Tu; Hsiao-Hui Chen; Ming-Yang Chang; Cheng-Chieh Hung
Journal:  Int Urol Nephrol       Date:  2016-08-05       Impact factor: 2.370

2.  Monitoring of the peritoneal membrane.

Authors:  Dirk G Struijk
Journal:  NDT Plus       Date:  2008-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.